Advanced glycation end products and cognitive impairment in schizophrenia.

Autor: Kobori A; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.; Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan., Miyashita M; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, Japan., Miyano Y; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan., Suzuki K; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, Japan., Toriumi K; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan., Niizato K; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan., Oshima K; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan., Imai A; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan., Nagase Y; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, Japan., Yoshikawa A; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan., Horiuchi Y; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan., Yamasaki S; Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan., Nishida A; Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan., Usami S; Graduate School of Education, University of Tokyo, Bunkyo-ku, Tokyo, Japan., Takizawa S; Division of Neurology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Itokawa M; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan., Arai H; Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan., Arai M; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2021 May 26; Vol. 16 (5), pp. e0251283. Date of Electronic Publication: 2021 May 26 (Print Publication: 2021).
DOI: 10.1371/journal.pone.0251283
Abstrakt: Advanced glycation end products play a key role in the pathophysiology of schizophrenia. Cognitive impairment is one of the central features of schizophrenia; however, the association between advanced glycation end products and cognitive impairment remains unknown. This study investigated whether advanced glycation end products affect the cognitive domain in patients with schizophrenia. A total of 58 patients with chronic schizophrenia were included in this cross-sectional study. Plasma advanced glycation end products were measured using high-performance liquid chromatography (HPLC). Neuropsychological and cognitive functions were assessed using the Wechsler Adult Intelligence Scale, Third Version, and the Wisconsin Card Sorting Test Keio-FS version. Multiple regression analysis adjusted for age, sex, body mass index, educational years, daily dose of antipsychotics, and psychotic symptoms revealed that processing speed was significantly associated with plasma pentosidine, a representative advanced glycation end product (standardized β = -0.425; p = 0.009). Processing speed is the cognitive domain affected by advanced glycation end products. Considering preceding evidence that impaired processing speed is related to poor functional outcome, interventions targeted at reducing advanced glycation end products may contribute to promoting recovery of patients with schizophrenia as well as cognitive function improvement.
Competing Interests: Dr. Kobori reports support from grants from the Japan Society for the Promotion of Science (JSPS) during the conduct of the study. Dr. Miyashita reports support from grants from JSPS during the conduct of the study and others from Kowa Co. Ltd., outside of the scope of the submitted work. Dr. Niizato reports the receipt of personal fees from Eisai, Daiichi-Sankyo, and Ono outside the scope of the submitted work. Dr. Imai reports personal fees from Otsuka and Meiji outside the scope of the submitted work. Dr. Nagase reports personal fees from Otsuka, Takeda, MSD, Eisai, Lily, Sumitomo Dainippon Pharma, Pfizer, Meiji, Yoshitomi, Novartis, Janssen, and Lundbeck outside the scope of the submitted work. Dr. Itokawa reports personal fees from Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, Pfizer, and CHUGAI outside the scope of the submitted work. Dr. Heii Arai reports personal fees from Takeda, MSD, Eisai, Lilly, Novartis, and Daiichi-Sankyo outside the scope of the submitted work. Dr. Makoto Arai reports grants from JSPS, the Uehara Memorial Foundation, and the Sumitomo Foundation during the conduct of the study, and others from Kowa Co. Ltd. outside the scope of the submitted work. Drs. Miyashita, Itokawa, and Arai have a patent (PCT/JP2008/063803) with royalties paid to Kowa Co. Ltd.; however, this will not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors declare no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: